Biotech | May 07, 2022
Gut microbiome as a tool in regenerative medicine
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Deputy Mayor from Addis Ababa (Ethiopia) battled out a rare laryngeal cancer at Yashoda Hospitals Hyderabad
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
The launch is yet another first of its kind innovation in India
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
Subscribe To Our Newsletter & Stay Updated
